Jasper Yuen
Family · Albany, NYNPI 1346900362
Payments from drug & device makers
Across 257 payments — averaging $19.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$707
- AstraZeneca$662
- Novo Nordisk$581
- AbbVie$571
- Lilly USA, LLC$460
- Exact Sciences$271
- plus $2K from 33 others
What the payments were for
- Food & beverage$5,037100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 39 | $707 |
| AstraZeneca | 22 | $662 |
| Novo Nordisk | 27 | $581 |
| AbbVie | 36 | $571 |
| Lilly USA, LLC | 26 | $460 |
| Exact Sciences | 11 | $271 |
| Amgen | 13 | $224 |
| Phathom Pharmaceuticals, Inc. | 11 | $157 |
| Bayer | 9 | $153 |
| Boehringer Ingelheim | 6 | $108 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $92 |
| Sanofi-aventis U.S. LLC | 2 | $82 |
| Optinose US, Inc. | 4 | $73 |
| Axsome Therapeutics, Inc. | 4 | $72 |
| Pfizer | 3 | $64 |
| Halozyme Inc | 3 | $58 |
| Dexcom, Inc. | 3 | $56 |
| Sumitomo Pharma America, Inc. | 3 | $55 |
| Abbott | 3 | $52 |
| IBSA Pharma Inc. | 3 | $52 |
| Astellas Pharma US Inc | 2 | $43 |
| Seqirus USA Inc | 2 | $43 |
| Lundbeck LLC | 2 | $40 |
| UCB, Inc. | 1 | $35 |
| Paratek Pharmaceuticals, Inc. | 2 | $35 |
| Mannkind Corporation | 2 | $34 |
| Merck | 2 | $31 |
| Viiv Healthcare Company | 1 | $24 |
| Antares Pharma, Inc. | 1 | $24 |
| Tolmar, Inc. | 1 | $23 |
| Johnson & Johnson | 1 | $21 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Aimmune Therapeutics, Inc. | 1 | $18 |
| Gilead | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Renalytix AI, Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$271
- FARXIGA$271
- BREZTRI$163
- TRELEGY ELLIPTA$119
How this compares
$5,037 in reported general payments places this provider in the 90th percentile of 8,883 family providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 67 | $134,369 |
| MounjaroTirzepatide | 41 | $69,272 |
| JardianceEmpagliflozin | 35 | $51,471 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 52 | $40,980 |
| EliquisApixaban | 26 | $40,405 |
| FarxigaDapagliflozin Propanediol | 27 | $37,946 |
| JanuviaSitagliptin Phosphate | 11 | $18,765 |
| MyrbetriqMirabegron | 11 | $9,773 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $5,729 |
| Doxepin Hcl | 13 | $3,476 |
| Celecoxib | 48 | $2,952 |
| Atorvastatin Calcium | 287 | $2,624 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 62 | $2,367 |
| SynthroidLevothyroxine Sodium | 38 | $2,308 |
| Levothyroxine Sodium | 135 | $2,223 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $581 | $134,36967 claims |
| Lilly USA, LLCMounjaro | $460 | $69,27241 claims |
| Boehringer IngelheimJardiance | $108 | $51,47135 claims |
| GSKTrelegy Ellipta | $707 | $40,98052 claims |
| PfizerEliquis | $64 | $40,40526 claims |
| AstraZenecaFarxiga | $662 | $37,94627 claims |
| MerckJanuvia | $31 | $18,76511 claims |
| Astellas Pharma US IncMyrbetriq | $43 | $9,77311 claims |
| AbbVieSynthroid | $571 | $2,30838 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,883 family providers in New York.
Other family in Albany
- Yvonne Fuller-FontenotAlbany$73K
- Christina NalboneNew York$197K
- Casey GrilloNew York$191K
- Suzanne WilsonIthaca$179K
- Jonathan LesuerSyracuse$172K
- Sheri HillNorth Syracuse$165K
- Cathrine CurtinBronxville$155K
- Mary Sullivan-WhalenNew York$137K
- Sarah AljahmiRockville Centre$87K
- John de OcaStaten Island$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.